New Delhi, Jan. 21 -- Sigachi Industries share price rebounded from its intraday low on Wednesday following the announcement of progress on a new combination of Active Pharmaceutical Ingredients (APIs) for Cystic Fibrosis (CF), which includes Vanzacaftor, Tezacaftor, and Deutivacaftor.

The company projects a revenue potential of around Rs.250 crore per year starting from the fourth quarter of FY2026-27, positioning this portfolio as a significant driver of growth.

The company announced in an exchange filing that this advancement represents a significant milestone in Sigachi's strategic aim to enhance its footprint in complex, high-value specialty APIs, in line with the global need for advanced treatments in rare and chronic diseases.

A...